Related Experiment Video
Updated: Jun 16, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Update on castrate-resistant prostate cancer: 2010.
1Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, District of Columbia 20007, USA. kiranlassi@yahoo.com
Current Opinion in Oncology
|February 24, 2010
Summary
Novel treatments for metastatic castration-resistant prostate cancer (CRPC) show mixed results. While some agents disappointed, others like Abiraterone and MDV3100 offer hope, with circulating tumor cells aiding prognosis.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer is a leading cause of morbidity and mortality in Western countries.
- Metastatic castration-resistant prostate cancer (CRPC) has a median survival of 1-2 years.
- Docetaxel-based therapies have shown survival improvements.
Purpose of the Study:
- To review novel agents for metastatic castration-resistant prostate cancer (CRPC).
- To discuss new cytotoxic agents, immunotherapies, circulating tumor markers, and targeting agents.
Main Methods:
- Review of recent clinical trial data and emerging therapeutic strategies.
- Analysis of promising agents in the phase III setting.
- Evaluation of the role of circulating tumor markers.
Main Results:
- Some promising agents yielded disappointing phase III results (e.g., GVAX).
- High expectations remain for agents like Abiraterone, MDV3100, Zibotentan, and immunotherapy.
- Circulating tumor cells provide significant prognostic information.
Conclusions:
- Systemic therapy options for CRPC are limited.
- Survival benefits of new therapies require further evaluation.
- Circulating tumor cells are crucial for future clinical decision-making in CRPC.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...